Compare CTRI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRI | MESO |
|---|---|---|
| Founded | 1909 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2024 | N/A |
| Metric | CTRI | MESO |
|---|---|---|
| Price | $25.85 | $18.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $23.25 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 2.2M | 185.3K |
| Earning Date | 11-05-2025 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $2,841,255,000.00 | $17,198,000.00 |
| Revenue This Year | $10.61 | $465.44 |
| Revenue Next Year | $9.02 | $75.37 |
| P/E Ratio | $1,021.94 | ★ N/A |
| Revenue Growth | 9.89 | ★ 191.39 |
| 52 Week Low | $14.46 | $9.61 |
| 52 Week High | $26.17 | $22.00 |
| Indicator | CTRI | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 75.52 | 64.81 |
| Support Level | $19.04 | $16.43 |
| Resistance Level | $20.76 | $17.65 |
| Average True Range (ATR) | 0.94 | 0.62 |
| MACD | 0.55 | 0.30 |
| Stochastic Oscillator | 95.58 | 93.07 |
Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. It operates under two primary lines of business which includes Gas Utility Services and Electric Utility Services it is also their two reportable segments as well.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.